Chitogenx Inc C.CHGX

Alternate Symbol(s): CHNXF

ChitogenX Inc. is a Canada-based emerging orthopedic and sports medicine biologics company. The Company is engaged in the development of therapeutic soft tissue repair technologies to improve the success rate of orthopedic and sports medicine surgeries. The Company’s proprietary biopolymer has been specifically designed to increase the healing rates of occupational and sports related injuries to tendons, ligaments, meniscus and cartilage. The biopolymer, autologous platelet-rich plasma (PRP) combination implant, can be directly placed into the site of injuries by surgeons during routine operative procedures without significantly extending the duration of surgeries and without further interventions. The Company assess its potential for therapeutic uses outside of the soft tissue repair market. The Company, through Ecole Polytechnique and two industrial partners, delineates the PRP components, the distinct impact of each component and their collective action towards tissue repair.

CSE:CHGX - Post by User

Chitogenx Inc > Business Update on its Ortho-R Rotator Cuff Program

<< Previous

Bullboard Posts

Next >>

Comment by RockLobster1on Aug 28, 2019 9:51am

145 Views

Post# 30074176

RE:Business Update on its Ortho-R Rotator Cuff Program

RockLobster1 wrote:

MONTREAL, Aug. 14, 2019 /CNW/ (CSE: ORTH) ("Ortho RTi" or the "Company"), an emerging Orthobiologics company, provided today a business update on its Ortho-R rotator cuff program.

Following a successful pre-IND meeting with the Food and Drug Administration ("FDA) in February 2019, the Company is now completing its preparation in order to start its rotator cuff Phase I/II clinical trial. The IND filing is anticipated by fiscal year-end. Ortho RTi started a 6-month pivotal preclinical study in January 2019 to provide the required data and address remaining FDA requirements in order to finalize the Phase I/II protocol. The in-life portion of the 6-month preclinical study as well as data collection have now been successfully completed. Final reporting is expected in the fall of 2019, along with other final IND requirements regarding manufacturing and stability.

"We are pleased to have completed this milestone according to schedule and look forward to updating our shareholders with the study results before year-end." said Claude LeDuc, President and Chief Executive Officer of Ortho RTi. "It is an exciting time for ORTHO RTI, as in parallel to the study, we continue working hard at multiple important deliverables in order to meet our coming IND submission timeline".